Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing
TRUMBULL, Conn. and EL MONTE, Calif., Feb. 9, 2024 /PRNewswire/ -- CooperSurgical®, a global leader in fertility and women's health, and Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that they have partnered to offer families of Cord Blood Registry® (CBR®) exclusive newborn genetic screening panels.
- CBR Portrait includes more than twice as many genes as CBR Snapshot and may identify more rare causes of these conditions.
- CBR Landscape also includes a pharmacogenetic (PGx) component, which is a type of genetic testing that can determine how a person breaks down or metabolizes certain medications.
- "Part of our mission is to use our resources and testing to improve the lives of those around us.
- Newborn genetic analysis serves as an illustration of this commitment, as early intervention may significantly improve health outcomes for many of these conditions."